FOLR1 and ovarian cancer: We next measured sFRα and anti-FRα IgG autoantibodies in the circulation of ovarian cancer patients at timepoint 1 (prior to the start of the treatment regimen, Fig. 1), compared with healthy subjects (Fig. 4).